Trial Profile
A Pilot, Open-label, Randomized, Two-Way Crossover, Single-Dose Bioequivalence Study of Pomalidomide Under Fasting Condition in Chinese Healthy Volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 12 Feb 2018
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Amyloid light-chain amyloidosis; Brain cancer; Multiple myeloma; Systemic scleroderma; Waldenstrom's macroglobulinaemia
- Focus Pharmacokinetics
- Sponsors Jiangsu Simcere Pharmaceutical
- 12 Feb 2018 New trial record